CN102676523B - 乳腺癌分子标志物miR-139-5p - Google Patents
乳腺癌分子标志物miR-139-5p Download PDFInfo
- Publication number
- CN102676523B CN102676523B CN201210153220.9A CN201210153220A CN102676523B CN 102676523 B CN102676523 B CN 102676523B CN 201210153220 A CN201210153220 A CN 201210153220A CN 102676523 B CN102676523 B CN 102676523B
- Authority
- CN
- China
- Prior art keywords
- mir
- reagent
- mammary cancer
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 45
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 45
- 108091029379 miR-139 stem-loop Proteins 0.000 title claims abstract description 29
- 108091046685 miR-139-1 stem-loop Proteins 0.000 title claims abstract description 29
- 108091049185 miR-139-2 stem-loop Proteins 0.000 title claims abstract description 29
- 239000003147 molecular marker Substances 0.000 title claims abstract description 13
- 210000002966 serum Anatomy 0.000 claims abstract description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 14
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 239000012807 PCR reagent Substances 0.000 claims description 9
- 238000003753 real-time PCR Methods 0.000 claims description 7
- 238000003757 reverse transcription PCR Methods 0.000 claims description 5
- 238000002123 RNA extraction Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 108091070501 miRNA Proteins 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 108090000468 progesterone receptors Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108091007780 MiR-122 Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- 108091062170 Mir-22 Proteins 0.000 description 1
- 108091093189 Mir-375 Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091051828 miR-122 stem-loop Proteins 0.000 description 1
- 108091091360 miR-125b stem-loop Proteins 0.000 description 1
- 108091058688 miR-141 stem-loop Proteins 0.000 description 1
- 108091029500 miR-183 stem-loop Proteins 0.000 description 1
- 108091088515 miR-197 stem-loop Proteins 0.000 description 1
- 108091061970 miR-26a stem-loop Proteins 0.000 description 1
- 108091007432 miR-29b Proteins 0.000 description 1
- 108091065159 miR-339 stem-loop Proteins 0.000 description 1
- 108091023791 miR-339-1 stem-loop Proteins 0.000 description 1
- 108091063340 miR-497 stem-loop Proteins 0.000 description 1
- 108091059456 miR-92-1 stem-loop Proteins 0.000 description 1
- 108091084336 miR-92-2 stem-loop Proteins 0.000 description 1
- 108091034121 miR-92a stem-loop Proteins 0.000 description 1
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210153220.9A CN102676523B (zh) | 2012-05-16 | 2012-05-16 | 乳腺癌分子标志物miR-139-5p |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210153220.9A CN102676523B (zh) | 2012-05-16 | 2012-05-16 | 乳腺癌分子标志物miR-139-5p |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102676523A CN102676523A (zh) | 2012-09-19 |
CN102676523B true CN102676523B (zh) | 2013-05-29 |
Family
ID=46809076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210153220.9A Active CN102676523B (zh) | 2012-05-16 | 2012-05-16 | 乳腺癌分子标志物miR-139-5p |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102676523B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101368213A (zh) * | 2008-10-13 | 2009-02-18 | 南京大学 | 血清微小核糖核酸试剂盒及其在乙肝早期诊断中的应用 |
CN201381322Y (zh) * | 2009-03-13 | 2010-01-13 | 广州华灿医药科技有限公司 | 一种快速miRNAs定量PCR检测试剂盒 |
CN101988060A (zh) * | 2009-07-30 | 2011-03-23 | 江苏命码生物科技有限公司 | 结直肠癌检测标记物及其检测方法、试剂盒和生物芯片 |
CN102439169A (zh) * | 2008-11-13 | 2012-05-02 | 复旦大学 | 用于结肠直肠癌的微rna表达谱分析的组合物和方法 |
-
2012
- 2012-05-16 CN CN201210153220.9A patent/CN102676523B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101368213A (zh) * | 2008-10-13 | 2009-02-18 | 南京大学 | 血清微小核糖核酸试剂盒及其在乙肝早期诊断中的应用 |
CN102439169A (zh) * | 2008-11-13 | 2012-05-02 | 复旦大学 | 用于结肠直肠癌的微rna表达谱分析的组合物和方法 |
CN201381322Y (zh) * | 2009-03-13 | 2010-01-13 | 广州华灿医药科技有限公司 | 一种快速miRNAs定量PCR检测试剂盒 |
CN101988060A (zh) * | 2009-07-30 | 2011-03-23 | 江苏命码生物科技有限公司 | 结直肠癌检测标记物及其检测方法、试剂盒和生物芯片 |
Non-Patent Citations (4)
Title |
---|
Debmalya Barh.Let-7, miR-125, miR-205, and miR-296 are prospective therapeutic agents in breast cancer molecular medicine.《Gene Ther Mol Biol》.2008,第12卷189-206. |
Let-7, miR-125, miR-205, and miR-296 are prospective therapeutic agents in breast cancer molecular medicine;Debmalya Barh;《Gene Ther Mol Biol》;20080930;第12卷;192 * |
Lorena Verduci.MicroRNA-mediated Interaction between Leukemia/Lymphoma-related Factor (LRF) and Alternative Splicing Factor/Splicing Factor 2 (ASF/SF2) Affects Mouse Embryonic Fibroblast Senescence and Apoptosis.《The Journal of Biological Chemistry》.2010,第285卷(第50期),39551–39563. |
MicroRNA-mediated Interaction between Leukemia/Lymphoma-related Factor (LRF) and Alternative Splicing Factor/Splicing Factor 2 (ASF/SF2) Affects Mouse Embryonic Fibroblast Senescence and Apoptosis;Lorena Verduci;《The Journal of Biological Chemistry》;20101210;第285卷(第50期);39553 * |
Also Published As
Publication number | Publication date |
---|---|
CN102676523A (zh) | 2012-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bardelli et al. | Liquid biopsies, what we do not know (yet) | |
Powrózek et al. | Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers | |
CN109890394A (zh) | 作为子宫内膜异位症的生物标志物的微小rna | |
US9944993B2 (en) | Method for enrichment of circulating tumor DNA and reagent for enrichment of circulating tumor DNA | |
Beasley et al. | Future perspectives of uveal melanoma blood based biomarkers | |
CN109609633A (zh) | 一种与乳腺癌辅助诊断相关的血清miRNA标志物及其应用 | |
KR20120132592A (ko) | 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트 | |
CN107519193A (zh) | 食管鳞癌早期分子诊断标志物及其应用 | |
CN102465176A (zh) | 一种快速检测HER-2 mRNA水平的荧光定量PCR诊断试剂盒 | |
CN102676522B (zh) | 乳腺癌分子标志物miR-195-5p | |
CN108753980A (zh) | 一种甲状腺微小乳头状癌的转移性筛查的筛查试剂盒 | |
CN107475386B (zh) | 用于诊治骨肉瘤的长链非编码rna标志物 | |
CN105063221A (zh) | 胃癌新型分子标志物krt18p55的检测及其应用 | |
Xu et al. | Expression of serum microRNA-378 and its clinical significance in laryngeal squamous cell carcinoma. | |
Zhuang et al. | c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis | |
EP3831963A1 (en) | Breast cancer early diagnosis and post-therapy monitoring method using liquid biopsy multiple cancer gene biomarkers | |
CN102676523B (zh) | 乳腺癌分子标志物miR-139-5p | |
CN105219841B (zh) | 一种肺癌差异性表达microRNA的检测试剂盒及其应用 | |
CN102676526B (zh) | 乳腺癌分子标志物miR-30c-1-3p | |
CN102676524B (zh) | 乳腺癌分子标志物miR-147a | |
CN102839172A (zh) | HIV感染疾病进展分子标志物miR-503 | |
CN109666741A (zh) | 一种新的胃癌标志基因circPTPDC1的应用 | |
RU2451937C2 (ru) | Способ диагностики рака молочной железы по уровню рнк интерлейкинов il-8 и/или il-18 в плазме крови | |
CN107916291A (zh) | lncRNA组合物及制备诊断预示三阴性型乳腺癌骨转移试剂盒的用途 | |
CN110257514A (zh) | 一种新的食管癌血液miRNA标志物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 100176 Beijing City, Beijing economic and Technological Development Zone Sheng Road No. 1 Building 2 Building 3 layer aipuyi Patentee after: BEIJING QUANTOBIO BIOTECHNOLOGY CO.,LTD. Address before: 100176 Beijing City, Daxing District Yizhuang economic and Technological Development Zone Sheng Road No. 1 Building 2 Building 3 layer aipuyi Patentee before: BEIJING QUANTOBIO BIOTECH Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Breast cancer molecular marker miR-139-5p Effective date of registration: 20181101 Granted publication date: 20130529 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING QUANTOBIO BIOTECHNOLOGY CO.,LTD. Registration number: 2018990001022 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200803 Granted publication date: 20130529 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING QUANTOBIO BIOTECHNOLOGY Co.,Ltd. Registration number: 2018990001022 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Molecular marker of breast cancer mir-139-5p Effective date of registration: 20200812 Granted publication date: 20130529 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING QUANTOBIO BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020990000948 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211201 Granted publication date: 20130529 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING QUANTOBIO BIOTECHNOLOGY CO.,LTD. Registration number: Y2020990000948 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220928 Address after: No. 12, Meiyuan Road, Huayuan Industrial Zone, Binhai New Area, Tianjin 300450 Patentee after: Union Stemcell & Gene Engineering Co.,Ltd. Address before: 100176 Beijing Economic and Technological Development Zone Patentee before: BEIJING QUANTOBIO BIOTECHNOLOGY CO.,LTD. |